linjc16/ctgov huggingface dataset:
Video Consultation During Follow up Surgical Care

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare the willingness to use and attitude towards VC amongst both patients with colorectal cancer and healthcare providers during follow up care. Second, to determine the satisfaction with the quality of the healthcare provider and the usability of the used VC technology. 50 patients will be asked to choose between video consultation or face-to-face contact at the outpatient surgical clinic.

Official Title
-----------------
Video Consultation During Follow up Care: Effect on Quality of Care and Patient- and Provider Attitude in Patients With Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Device: Video consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Fluent in speaking and writing in Dutch Follow up appointments in which overall progress, new complaints, results with good news and treatment was discussed were considered feasible. Exclusion Criteria: Introductory appointments Bad news consultations Physical examination needed No access to Internet No access to a smartphone, tablet or computer with a camera Not willing to activate their electronic patient portal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| F2F-Group<br>Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic. | |
| VC-group<br>Patients who preferred a video consult were seen over a video connection. | Device: Video consultation<br>* A two-way audio and visual connection between patients and surgeons<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attitude and satisfaction with video consultation | PAT-VC questionnaire | Immediately after the consult | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability of the video consultation technology | SUS questionnaire | Immediately after the test consult | 
| Quality of provided care by surgeon: MSF questionnaire | MSF questionnaire | Immediately after the consult | 
| Satisfaction of surgeons: Questionnaire | Questionnaire | Immediately after the consult | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Video Consultation, Virtual visits
Eligard Observational Registry for Patients With Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Eligard. Data collected through this national registry program provides an opportunity to increase knowledge of efficacy and safety of the long term treatment with Eligard, provide a platform to better identify patient segments for the therapy with Eligard®. Furthermore registries are the only tools to accurately capture rare adverse events.

Detailed Description
-----------------
354 patients were enrolled in this study. Only 88 patients completed the study. For those patients completing the three years of data collection, 10% were considered Castrate Resistant and remained on Eligard®. For those patients not completing 3 years of follow-up, 8.8% were considered Castrate Resistant and did not continue in the study.

Official Title
-----------------
A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.

Conditions
-----------------
Cancer of the Prostate

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients > 18 years of age. Histologically confirmed diagnosis of locally Advanced or Metastatic Prostate Cancer. Patient starting an androgen deprivation therapy with Eligard at 3 or 4 month treatment frequency per standard of care. Signed written informed consent. Exclusion Criteria: Prior ADT (within 6 months). Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol. Life expectancy less than 2 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the percentage of patients that will achieve a hormone refractory status at 3 years after initiation of Androgen Deprivation Treatment with Eligard®. |  | 3 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine what baseline patient characteristics are associated with becoming hormone refractory at 3 years. |  | 3 years | 
| Collect data on patient demographics, medical history, and change in prostate-, bone- and overall health of the patients receiving androgen ablation treatment using Eligard®. |  | 3 years | 
| Collect referral data if the patient was referred to a medical oncologist during treatment. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prostate cancer
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Study Overview
=================
Brief Summary
-----------------
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream The objective is to compare the efficacy and safety of the different treatment regimens

Detailed Description
-----------------
A phase IV study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) ointment following treatment with combination ointment in psoriasis vulgaris

Official Title
-----------------
Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: Calcipotriol, (calcipotriol + betamethasone)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with psoriasis vulgaris of trunk and/or limbs Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Calcipotriol, (calcipotriol + betamethasone)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of regimen (a) versus regimen (c) by % change in PASI at week 12 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of regimen (b) versus regimen (c) at week 12, safety of regimen (a) versus (c), safety of regimen (b) versus (c) |  |  |
Cell Free DNA in Mature B-cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.

Official Title
-----------------
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management

Conditions
-----------------
Mature B-Cell Lymphoma

Intervention / Treatment
-----------------
* Procedure: peripheral blood collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria 18 years or older Exclusion Criteria: Chemotherapy before Other tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| B-cell lymphoma<br> | Procedure: peripheral blood collection<br>* peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | 2-year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 2-year | 
| Complete Response rate |  | 6 weeks after treatment |
Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Study Overview
=================
Brief Summary
-----------------
Comparison of the effect on the progression of the carotid intima-media interphase thickness (GIM), arterial rigidity according to the measurement of the pulse wave speed and direct measurement of the carotid and aortic rigidities and an inflammation marker (PCR) in patients with established cardiovascular disease (myocardial infarct, atherosclerotic coronary disease), diabetes mellitus type 2 or equivalent risk of coronary disease and a low density lipoprotein level > 100 mg/dL, treated with simvastatin, pravastatin or the combination of simvastatin-ezetimibe during a period of at least one year.

Official Title
-----------------
Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Drug: ezetimibe (+) simvastatin
* Drug: simvastatin
* Drug: pravastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ldl-C Levels >100 Mg/Dl Patients Who Have Signed The Consent Patients Of ages between 30 and 75 Years Old Patients Of Both Genders Patients With Established Cardiovascular Disease, Diabetes With Or Without Established Cardiovascular Disease Patients Without Previous Treatment With Ezetimibe

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>Group A: Comparator | Drug: simvastatin<br>* Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets<br>* Other names: Zocor;|
| Active Comparator: B<br>Group B: Comparator | Drug: pravastatin<br>* Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets<br>|
| Experimental: C<br>Group C: Drug | Drug: ezetimibe (+) simvastatin<br>* Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets<br>* Other names: Vytorin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The annual progression of the slope of the maximum average GIM and the arterial rigidity. |  | 1 Year |
Pharmacotherapy and Psychotherapy in the Treatment of Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
The study involved the administration of pharmacotherapy and cognitive behavior psychotherapy to individuals suffering from erectile dysfunction. The study was randomized controlled trial with four arms involving a control group.

Official Title
-----------------
A Comparison of Pharmacotherapy and Psychotherapy in the Treatment of Erectile Dysfunction

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Drug: Sildenafil Citrate 50Mg Tab
* Behavioral: Cognitive Behavioral Psychotherapy
* Combination Product: Combined or Integrated Therapy
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men diagnosed with erectile dysfunction Must be in the age range of 18 to 40 years Must be in a stable heterosexual relationship Must not be suffering from any medical or psychiatric illness Exclusion Criteria: Men not meeting criteria of diagnosis of erectile dysfunction Men not in a heterosexual relationship Men above the age of 40 years Men diagnosed with any medical or psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>This arm received pharmacotherapy for erectile dysfunction. | Drug: Sildenafil Citrate 50Mg Tab<br>* The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.<br>|
| Experimental: Group B<br>This arm received cognitive behavior psychotherapy for erectile dysfunction. | Behavioral: Cognitive Behavioral Psychotherapy<br>* The Group B received cognitive behavior psychotherapy for a period of max 3 months.<br>|
| Experimental: Group C<br>This arm received combined treatment approach. | Combination Product: Combined or Integrated Therapy<br>* The Group C received the combined therapeutic approach for a period of max 3 months.<br>|
| Placebo Comparator: Group D<br>This arm acted as a control group and received placebo or no intervention. | Other: Placebo<br>* The Group D received no treatment or placebo for a period of max 3 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| International Index of Erectile Functioning-5 |  | 3 months maximum |
Effects of a Therapeutic Education Program on Treatment Adherence Among Patients Prescribed At-home CPAP or At-home NIV

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to study the effect of therapeutic education on patient adherence for at-home continuous positive airway pressure (CPAP) or at-home non-invasive ventilation. This first study will use data already present in the Association for Home Assistance and Rehabilitation (APARD) database to compare patients who received therapeutic education with a control group who did not.

Detailed Description
-----------------
The proposed study calendar refers to the beginning and completion of work on the APARD database.

Official Title
-----------------
Effects of a Therapeutic Education Program on Treatment Adherence Among Patients Prescribed At-home Continuous Positive Airway Pressure or At-home Non-invasive Ventilation

Conditions
-----------------
Continuous Positive Airway Pressure, Noninvasive Ventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that have been equipped by the Association for Home Assistance and Rehabilitation (APARD) with either a continuous positive airway pressure (CPAP) device or a non-invasive ventilation (NIV) device. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| With therapeutic education<br>Patients assigned to this group will have participated in a therapeutic education program. | |
| Without therapeutic education (control)<br>Patients assigned to this (control) group have not had any kind of therapeutic education. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment adherence | Treatment adherence will be quantified as the average number of hours of device usage per night | a period of 28 days (retrospective study) |
Chest Physiotherapy in Pediatrics Patients With Pneumonia

Study Overview
=================
Brief Summary
-----------------
Chest physiotherapy has been used to treat pediatric patients hospitalized with pneumonia however there was no evidence to support a beneficial effect in pediatric patients.

Official Title
-----------------
Chest Physiotherapy in Pediatric Patients Hospitalised With Community-acquired Pneumonia: a Randomized Clinical Trial

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Other: Physiotherapy
* Other: Positioning and cough


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 1 to 12 years with acute community-acquired pneumonia (cough, tachypnea, fever and with a chest radiography with lobar, segmental or bronchopneumonia within the first 48 hours) Exclusion Criteria: Severely ill patients (hospitalized in intensive care units) Pleural effusion treated with chest drainage Atelectasis detected by x-ray Pneumonia or pleural effusion in the previous six months Other pulmonary underlying disease, heart disease, cerebral palsy or immune deficiency

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay. | Other: Positioning and cough<br>* Non-mandatory request to maintain lateral positioning to improve air exchange and cough<br>|
| Experimental: Physiotherapy<br>Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission. | Other: Physiotherapy<br>* Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physiotherapy, children, clinical trial
Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours

Study Overview
=================
Brief Summary
-----------------
Assess efficacy of vardenafil within 6 hours after intake

Official Title
-----------------
An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Drug: Levitra (Vardenafil, BAY38-9456)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18 years and older Males with erectile dysfunction Stable heterosexual relationship Exclusion Criteria: Primary hypoactive sexual desire- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months Nitrate use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Levitra (Vardenafil, BAY38-9456)<br>* Vardenafil 10mg orally on demand prior to intercourse<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful attempt rate reported between drug ingestion and a maximum of 6 hours after drug intake |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| International Index of Erectile Function |  | 12 weeks | 
| Global Assessment Question (GAQ) |  | 12 weeks | 
| Other diary responses |  | 12 weeks | 
| General Safety |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Male Erectile Dysfunction, Vardenafil